Metraipolis › archive › dc_afb9ca64c370
Case Series: Combination of dupilumab and omalizumab as a way to reduce dupilumab-associated adverse events in severe atopic dermatitis — Europe PMC PMID:41626198
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41626198
- DOI
- 10.3389/falgy.2025.1696897
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T18:09:44.028Z
- SHA-256 of the archived text
ebad52eff969fd552e03cbfeb6ec88824c1d2265a2e33167fce38ec5318f6d6f- Stable URL of this page
https://metraipolis.com/documento/dc_afb9ca64c370
How to cite
Case Series: Combination of dupilumab and omalizumab as a way to reduce dupilumab-associated adverse events in severe atopic dermatitis — Europe PMC PMID:41626198 — Europe PMC (en), https://europepmc.org/article/MED/41626198 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_afb9ca64c370 (Metraipolis archive dc_afb9ca64c370, sha256 ebad52eff969fd552e03cbfeb6ec88824c1d2265a2e33167fce38ec5318f6d6f)
BibTeX
@misc{dcafb9ca64c370,
title = {Case Series: Combination of dupilumab and omalizumab as a way to reduce dupilumab-associated adverse events in severe atopic dermatitis — Europe PMC PMID:41626198},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41626198},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_afb9ca64c370; sha256 ebad52eff969fd552e03cbfeb6ec88824c1d2265a2e33167fce38ec5318f6d6f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41626198. Agents can read the archived copy with the MCP tool read_document.